7BIO

TargetMol
Product Code: TAR-T22012
Supplier: TargetMol
CodeSizePrice
TAR-T22012-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22012-2mg2mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22012-5mg5mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22012-1mL1 mL * 10 mM (in DMSO)£130.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22012-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22012-25mg25mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22012-50mg50mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22012-100mg100mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T22012-500mg500mg£938.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
CAS:
916440-85-2
Formula:
C16H10BrN3O2
Molecular Weight:
356.179
Pathway:
Tyrosine Kinase/Adaptors; Chromatin/Epigenetic; Angiogenesis; Cell Cycle/Checkpoint
Purity:
0.9977
SMILES:
ON=C1C(Nc2ccccc12)=C1C(=O)Nc2c1cccc2Br
Target:
FLT; DYRK; Aurora Kinase

References

1. Ribas J, Bettayeb K, Ferandin Y, et al. 7-Bromoindirubin-3?-oxime induces caspase-independent cell death[J]. Oncogene, 2006, 25(47): 6304-6318. 2. Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, et al. Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases[J]. ACS medicinal chemistry letters, 2012, 4(1): 22-26. 3. Myrianthopoulos V, Magiatis P, Ferandin Y, et al. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins[J]. Journal of medicinal chemistry, 2007, 50(17): 4027-4037.